HBIO Key Statistics, Chart & Performance
The current stock price of HBIO is 0.6304 USD. In the past month the price decreased by -17.55%. In the past year, price decreased by -66.82%.
HBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.63 | 232.51B | ||
| DHR | DANAHER CORP | 30.92 | 168.37B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 200.78 | 61.01B | ||
| IQV | IQVIA HOLDINGS INC | 20.84 | 41.28B | ||
| A | AGILENT TECHNOLOGIES INC | 26.62 | 42.11B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.5 | 30.34B | ||
| WAT | WATERS CORP | 31.24 | 23.62B | ||
| ILMN | ILLUMINA INC | 32.36 | 21.56B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.97 | 19.82B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.61 | 16.76B | ||
| TEM | TEMPUS AI INC | N/A | 11.79B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B |
Related stock screener links
About HBIO
Company Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Company Info
HARVARD BIOSCIENCE INC
84 October Hill Rd
Holliston MASSACHUSETTS 01746 US
CEO: James Green
Employees: 330
Phone: 15088938999
HARVARD BIOSCIENCE INC / HBIO FAQ
What does HARVARD BIOSCIENCE INC do?
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Can you provide the latest stock price for HARVARD BIOSCIENCE INC?
The current stock price of HBIO is 0.6304 USD. The price decreased by -3.3% in the last trading session.
What is the dividend status of HARVARD BIOSCIENCE INC?
HBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of HBIO stock?
HBIO has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for HBIO stock?
The Revenue of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -8.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does HARVARD BIOSCIENCE INC have?
HARVARD BIOSCIENCE INC (HBIO) currently has 330 employees.
Can you provide the ownership details for HBIO stock?
You can find the ownership structure of HARVARD BIOSCIENCE INC (HBIO) on the Ownership tab.
HBIO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HBIO. When comparing the yearly performance of all stocks, HBIO is a bad performer in the overall market: 79.1% of all stocks are doing better.
HBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HBIO. Both the profitability and financial health of HBIO have multiple concerns.
HBIO Financial Highlights
Over the last trailing twelve months HBIO reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| Debt/Equity | 0 |
HBIO Forecast & Estimates
8 analysts have analysed HBIO and the average price target is 2.04 USD. This implies a price increase of 223.6% is expected in the next year compared to the current price of 0.6304.
For the next year, analysts expect an EPS growth of -49% and a revenue growth -8.37% for HBIO